Phase 3 N=585 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
Ulcerative Colitis
Primary: Partial Mayo Score: Change From Baseline Over Time — 2.5; -0.2; -0.4; -0.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,365 Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Pulmonary Embolism · Thromboembolism · Thrombosis
Primary: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism — 13; 17; 50; 8 participants — p=0.0001
Phase 2 N=258 OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
Depressive Disorder, Major
Primary: Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 31.4; 32.0; 32.4; 32.0 Scores on a Scale
N/A N=1,181 Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Human Immunodeficiency Virus Infection · Sexually Transmitted Diseases
Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008
N/A N=135 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Phase 3 N=299 Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
Hyperlipidemia
Primary: Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo — 6.2; -57.2…
Phase 2 N=28 Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI) — -0.008; 0.009 units on a scale — p=0.05
Phase 2 N=32 Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants
Phase 3 N=3,219 A Study of Vemurafenib in Participants With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
N/A N=812 ABSORB EXTEND Clinical Investigation
Myocardial Ischemia · Coronary Artery Stenosis · Coronary Disease
Primary: Number of Participants With Major Adverse Cardiac Events (MACE; Cardiac Death, Protocol MI, ID-TLR) — 14 Participants
N/A N=30 Spinal Cord Stimulation Frequency Study
Failed Back Surgery Syndrome
Primary: Visual Analog Scale (VAS) on Back Pain — 4.83; 4.51; 4.57; 3.22 units on a scale — p=0.002
Phase 3 N=130 Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
Influenza
Primary: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies — 58 Participants
N/A N=721 ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe
Mitral Valve (MV) Regurgitation
Primary: MR Severity — 0.0; 0.0; 0.0; 3.1 percentage of participants
N/A N=578 Analysis of the Acceptance and Changes to Parameters Programming Suggested by the TherapyGuide Function
Bradyarrhythmia
Primary: Acceptance of TherapyGuide Proposals and Typology of Programming Changes — 46 percentage of patients
N/A N=56 Medicinal Nicotine for Preventing Cue Induced Craving
Tobacco Use Disorder
Primary: Craving Symptom Severity Score Assessed Via Questionnaire — 0.52; 0.57; 0.31 units on a scale — p=0.25